About Altimmune
Altimmune is a company based in Gaithersburg (United States) founded in 1997 was acquired by PharmAthene in January 2017. Altimmune has raised $58 million across 23 funding rounds from investors including NIH, HHS and U.S Army. The company has 59 employees as of December 31, 2024. Altimmune has completed 1 acquisition, including Immune Targeting Systems. Altimmune operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Biological E, Mirum Pharmaceuticals and Adocia, among others.
- Headquarter Gaithersburg, United States
- Employees 59 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Altimmune, Inc.
-
Annual Revenue
$20 K (USD)-95.31as on Dec 31, 2024
-
Net Profit
-$95.06 M (USD)-7.48as on Dec 31, 2024
-
EBITDA
-$102.93 M (USD)-23.97as on Dec 31, 2024
-
Total Equity Funding
$58 M (USD)
in 23 rounds
-
Latest Funding Round
$4.7 M (USD), Grant
Jun 29, 2020
-
Investors
NIH
& 11 more
-
Employee Count
59
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
PharmAthene
(Jan 19, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Altimmune
Altimmune is a publicly listed company on the NASDAQ with ticker symbol ALT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Altimmune
Unlock access to complete
Unlock access to complete
Funding Insights of Altimmune
Altimmune has successfully raised a total of $58M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $4.7 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Altimmune
Altimmune has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and U.S Army.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Locked | Locked | Locked |
Investor details for Altimmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Altimmune
Altimmune has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immune Targeting Systems.
Investment portfolio details for Altimmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell vaccines against mutating viruses are discovered and developed.
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Altimmune
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Altimmune
Detailed financials for Altimmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Altimmune Comparisons
Peer comparison for Altimmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Altimmune
Altimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Biological E, Mirum Pharmaceuticals and Adocia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
Detailed competitors of Altimmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Altimmune
Complete news archive for Altimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altimmune
Altimmune was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Altimmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Vipin K Garg is the current CEO of Altimmune.
Altimmune is a funded company, having raised a total of $58M across 23 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Altimmune is 59.
Annual revenue of Altimmune is $20K as on Dec 31, 2024.
Altimmune was founded in 1997 and is based in Gaithersburg, United States, within the biotechnology sector. Focus is placed on developing vaccines and immunotherapies targeting infectious diseases like influenza and hepatitis B, alongside treatments for solid tumors and related conditions. Products under development include NasoVAX for intranasal influenza vaccination, HepTcell for chronic hepatitis B, ALT-801 for non-alcoholic steatohepatitis, T-COVID for intranasal COVID-19 therapy, and NasoShield for anthrax protection.
Altimmune's top competitors include Nimbus Therapeutics, Adocia and Biological E.
Yes, Altimmune is publicly traded on NASDAQ under the ticker symbol ALT.
Altimmune has made 1 acquisition, including Immune Targeting Systems.
Altimmune has 12 investors. Key investors include NIH, HHS, U.S Army, PharmAthene, and Truffle Capital.
The ticker symbol of Altimmune is ALT on NASDAQ.